Allergan Chooses Dendrite's SalesPlus for Five Sales Teams.

MORRISTOWN, NJ--(BUSINESS WIRE)--May 26, 1999--

Dendrite Signs First West Coast

Pharmaceutical Company to Three Year Deal

Dendrite International, Inc. (NASDAQ/NMS:DRTE) today announced that its SalesPlus Americas division has signed a licensing agreement with Allergan, Inc. (NYSE:AGN), a research-based, global healthcare company based in Irvine California, to provide software and support services for Allergan's multi-disciplinary North American sales representatives.

This contract, covering 330 reps, will supply Allergan's five discrete sales teams with SalesPlus software and services. SalesPlus, the new division of Dendrite for Mid-Range Pharmaceutical and Biotech companies in the US, offers full-function, focused tools designed to deliver maximum results. This innovative sales tool configures and delivers sales force effectiveness (SFE) systems in faster timeframes.

John LaHaye, Senior Vice President of Dendrite, provided Allergan with a `commitment to performance.' "We will provide end-to-end support to Allergan," LaHaye said. "Our fully integrated service model will meet all of Allergan's sales force effectiveness needs and we're looking forward to globally expanding our relationship with this important player in the pharmaceutical industry." Allergan markets to over 100 countries, and SalesPlus is confident they will be able to provide solutions to any of Allergan's global needs.

SalesPlus was selected over newer and traditional front-office vendors. Mike Ball, President of Allergan North America, said, "SalesPlus was the best choice for Allergan on many levels. First, SalesPlus offers a full understanding of pharmaceutical sales force best practices, and we plan to take advantage of that expertise to build the best system for our sales force. Second, going with SalesPlus and their focus on the vertical pharmaceutical market, our risk factors were minimized given their experience with deploying and completing sales force roll-outs."

ABOUT ALLERGAN

Founded in 1948, Allergan became a public company in 1970, merged with SmithKline Beckman in 1980, and was reestablished as an independent entity in 1989. Allergan, Inc. common stock is traded on the New York Stock Exchange under the symbol AGN.

Allergan, Inc. headquartered in Irvine, California, is a technology driven, global health care company, providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to its customers, satisfy unmet needs and improve patients' lives.

Allergan targets its products and R&D to specific disease areas. These include glaucoma and retinal disease, cataracts, dry eye, psoriasis, acne, photodamage, movement disorders, pain, metabolic disease and various types of cancer. Leading-edge technologies in which the Company has established leadership positions include second-generation alpha2 agonist compounds, receptor-selective retinoids, foldable intraocular lenses (IOLs), injectable neurotoxin and convenient contact lens care products.

Allergan markets products in more than 100 countries. In 1998, sales outside the United States generated approximately 54% of the Company's $1.25 billion worldwide revenue.

Leading products: Allergan's leading products include:

A novel treatment for glaucoma and ocular hypertension The first US-FDA approved multifocal small incision intraocular lens and a comprehensive line of advanced phacoemulsification equipment for cataract surgery. A complete line of OTC products for dry eye A topical retinoid for the treatment of plaque psoriasis and acne A broad line of contact lens care products BOTOX(R) (Botulinum Toxin Type A) Purified Neurotoxin Complex

For more information, visit the Company's Web site: http://www.allergan.com.

ABOUT DENDRITE

With a strong focus on outcomes in the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite is a leading global provider of highly-specialized, integrated product and service offerings to support strategies for a sustained competitive advantage. Thousands of sales representatives and their managers in over 150 companies in 17 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. The Company uses its highly specialized industry knowledge to develop modular software products that enhance sales force effectiveness. The products, combined with specifically tailored coaching and support services, focus sales representatives on improving their performance. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception.

Headquartered in Morristown, New Jersey, Dendrite employs over 850 people all around the world. For more information, visit the Company's Web site: http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release may contain statements that, if not verifiable historical fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Dendrite and its business. The predictions embodied in these statements will involve risks and uncertainties and, accordingly, Dendrite's actual results may differ significantly from the results discussed or implied in such forward-looking statements.